Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

Summary

This is an open-label, single center, one cohort, non-randomized, phase II study. The aim is to evaluate the efficacy and safety of the combination of hypofractionated radiotherapy (HRT) and pembrolizumab on local tumor control in mucosal melanoma patients. Treatment effect will be compared with historical radiation therapy-alone control data.

Timeline

Start

2020-05-29

Primary completion

2030-07-31

Completion

2032-07-31

Drugs

Indications